Latest Content

A study reveals only 18.3% of young adults with advanced cancer receive palliative care, highlighting a critical gap for oncology nurses to address.

New research identifies treatment initiation thresholds that impact 3-year metastasis risk in colorectal cancer patients across distinct pathways.

In the phase 3 RASolute 302 trial, oral KRAS inhibitor daraxonrasib nearly doubled median overall survival to 13.2 months in pancreatic cancer.

Oncology nurses discuss managing lung cancer as a chronic disease, addressing long-term symptoms, financial toxicity, and psychosocial care.

The FDA approved zidesamtinib for metastatic ROS1-positive NSCLC following prior kinase inhibitor therapy, offering hope for patients with resistance.

A Neurology study reveals breast cancer survivors have a high ischemic stroke risk within one year of diagnosis, linked to specific treatment regimens.

Stephanie Desrosiers discusses strategies for oncology nurses to manage chemotherapy shortages, ensuring patient safety, equity, and mental health.

NYU Langone experts discuss multidisciplinary care, diagnostic challenges, and nursing's role in treating rare bone and soft tissue sarcomas.

A 10-year study of 3,477 patients reveals focal therapy offers high survival and low metastasis for localized prostate cancer with few side effects.

NATCO Pharma receives tentative U.S. FDA approval for a generic version of the PARP inhibitor olaparib (Lynparza) for oncology indications.

Kevin Brigle, PhD, ANP, discusses frontline quads, managing toxicities of bispecifics, and the evolving role of nursing in multiple myeloma treatment.

Linda Casey, RN, shares essential strategies for oncology nurses to protect vulnerable patients from the clinical risks of wildfire smoke exposure.

Drs. Sledge and Pastorini discuss how AI-powered molecular profiling corrected a misdiagnosis and the vital "early warning" role of oncology nurses.